ClinicalTrials.gg
CompletedNCT00572611Updated Sep 26, 2012

Human Mass Balance Study With Bilastine

A Phase 1 interventional study of [14C]-bilastine in Healthy, sponsored by Faes Farma, S.A.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-09-26.

Sponsored by Faes Farma, S.A. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
Male
01

Study summary

The primary objective of the study is to define the absorption and excretion kinetics of bilastine in man following oral administration, and to investigate the nature of the metabolites present in plasma and excreta. The secondary objective of the study is to assess the safety and tolerability of bilastine

Read the detailed description

Primary Endpoints are: Whole blood and plasma concentrations of total radioactivity and parent drug. Urine and faecal recovery of total radioactivity. Characterisation and identification of metabolites in plasma, urine and faeces.

02

Conditions studied

  • Healthy

Keywords

  • Mass Balance
  • Metabolism
  • Absorption
  • Excretion
  • Pharmacokinetics
03

In context

Lead sponsor

Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No abnormal physical findings.
  • No clinically significant abnormalities in the results of laboratory evaluation.
  • Normal .
  • Normal supine blood pressure and heart rate.
  • Body weight between 50 and 100 kg and between 18 and 30 kg/m2.
  • Able to communicate well with the investigator and to comply with the requirements of the entire study.
  • Provision of written to participate.
  • Subjects must agree to use an adequate method of during the study and for 12 weeks after dosing.
  • Subjects must have a negative urine screen for drugs of abuse.
  • Subjects must have a regular bowel habit.

Exclusion criteria

Exclusion Criteria:

  • Administration of any IMP within 12 weeks before entry to the study.
  • Use of any prescribed medication or St John's Wort within 14 days or OTC medication within 5 days of dosing.
  • Existence of any surgical or medical condition which, in the judgement of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the IMP.
  • History of any drug or alcohol abuse in the past 2 years, or alcohol consumption greater than 21 units per week.
  • Presence or history of allergy requiring treatment.
  • Hayfever is allowed unless it is active or has required treatment within the previous 2 months.
  • Donation or loss of greater than 400 mL of blood within 12 weeks before entry to the study.
  • Serious adverse reaction or serious to any drug.
  • Presence of surface antigen (HBsAg), antibody (HCV Ab) or 1 or HIV 2 antibodies at screening.
  • Administration of radiolabelled substances or exposure to significant radiation (eg serial x-ray or CT scans, barium meal etc) within the past 12 months.
  • Any abnormality at screening (including of >430 ms).
  • Past medical history of ECG abnormalities, or a family history of a prolonged QT interval syndrome.
  • Abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.
  • Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine, etc.) within 2 months prior to or during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    I

    Single oral dose of 20 mg \[14C\]-bilastine

    Drug: [14C]-bilastine

Interventions

  • Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only

06

What researchers measure

Primary outcomes

  1. Whole blood and plasma concentrations of total radioactivity and parent drug

    Time frame: 168-216 h after dosing, depending on the radioactivity recovery

  2. Urine and faecal recovery of total radioactivity

    Time frame: 168-216 h after dosing, depending on the radioactivity recovery

  3. Characterisation and identification of metabolites in plasma, urine and faeces

    Time frame: 168-216 h after dosing, depending on the radioactivity recovery

07

Study locations

1 site
  • Charles River Laboratories Clinical Services Ltd, Origo Centre
    Riccarton, Edinburgh EH14 4AP, United Kingdom
08

References and documents

Publications

  • Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:18-24. doi: 10.3109/01480545.2012.682651. Erratum In: Drug Chem Toxicol. 2012 Oct;35(4):472. PubMed 22616812 ↗
  • Lucero ML, Patterson AB. Whole-body tissue distribution of total radioactivity in rats after oral administration of [(1)(4)C]-bilastine. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:1-7. doi: 10.3109/01480545.2012.682650. Erratum In: Drug Chem Toxicol. 2012 Oct;35(4):472. PubMed 22616810 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2007
First posted
Dec 13, 2007
Start
Nov 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Sep 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00572611
Lead sponsor
Faes Farma, S.A.
Collaborators
Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical Services Ltd, MDS Pharma Services Switzerland AG
Responsible party
Sponsor
First posted
Dec 13, 2007
Start date
Nov 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Sep 26, 2012

Study contacts

Stuart J Mair, MD
principal investigator · Syneos Health
Lindsay McGregor
study director · Syneos Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion